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Background: Acquired resistance to endocrine therapy in breast cancer is a significant problem with relapse being
associated with local and/or regional recurrence and frequent distant metastases. Breast cancer cell models reveal
that endocrine resistance is accompanied by a gain in aggressive behaviour driven in part through altered growth
factor receptor signalling, particularly involving erbB family receptors. Recently we identified that CD44, a
transmembrane cell adhesion receptor known to interact with growth factor receptors, is upregulated in
tamoxifen-resistant (TamR) MCF7 breast cancer cells. The purpose of this study was to explore the consequences of
CD44 upregulation in an MCF7 cell model of acquired tamoxifen resistance, specifically with respect to the
hypothesis that CD44 may influence erbB activity to promote an adverse phenotype.
Methods: CD44 expression in MCF7 and TamR cells was assessed by RT-PCR, Western blotting and
immunocytochemistry. Immunofluorescence and immunoprecipitation studies revealed CD44-erbB associations.
TamR cells (± siRNA-mediated CD44 suppression) or MCF7 cells (± transfection with the CD44 gene) were treated
with the CD44 ligand, hyaluronon (HA), or heregulin and their in vitro growth (MTT), migration (Boyden chamber
and wound healing) and invasion (Matrigel transwell migration) determined. erbB signalling was assessed using
Western blotting. The effect of HA on erbB family dimerisation in TamR cells was determined by
immunoprecipitation in the presence or absence of CD44 siRNA.
Results: TamR cells overexpressed CD44 where it was seen to associate with erbB2 at the cell surface.
siRNA-mediated suppression of CD44 in TamR cells significantly attenuated their response to heregulin, inhibiting
heregulin-induced cell migration and invasion. Furthermore, TamR cells exhibited enhanced sensitivity to HA, with
HA treatment resulting in modulation of erbB dimerisation, ligand-independent activation of erbB2 and EGFR and
induction of cell migration. Overexpression of CD44 in MCF7 cells, which lack endogenous CD44, generated an
HA-sensitive phenotype, with HA-stimulation promoting erbB/EGFR activation and migration.
Conclusions: These data suggest an important role for CD44 in the context of tamoxifen-resistance where it may
augment cellular response to erbB ligands and HA, factors that are reported to be present within the tumour
microenvironment in vivo. Thus CD44 may present an important determinant of breast cancer progression in the
setting of endocrine resistance.
Keywords: Tamoxifen-resistance, CD44, erbB, Hyaluronan, Heregulin* Correspondence: HiscoxSE1@cf.ac.uk
†Equal contributors
1Welsh School of Pharmacy, Cardiff University, Wales, UK
Full list of author information is available at the end of the article
© 2012 Hiscox et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hiscox et al. BMC Cancer 2012, 12:458 Page 2 of 14
http://www.biomedcentral.com/1471-2407/12/458Background
Widespread improvements in the treatment of estrogen
receptor (ER)-positive breast cancer have been seen fol-
lowing the introduction of endocrine agents such as
tamoxifen. Although recent clinical data point to the po-
tential advantages of aromatase inhibitors over tamoxi-
fen in some cases, tamoxifen remains a relevant and
important intervention strategy, particularly for younger
patients [1]. However, despite this, for a significant num-
ber of ER+ patients, their prognosis remains poor due to
acquired resistance [2]. Whilst adjuvant endocrine ther-
apy inhibits cell cycle progression in residual tumour
cells, these agents are less effective at inducing cell death
[3,4]. Thus chronic exposure of residual tumour cells to
endocrine treatments may promote adaptive changes
which ultimately facilitate development of a resistant
phenotype [5]. In vitro, in vivo and clinical studies have
provided an insight into mechanisms underlying acquisi-
tion of endocrine resistance and provide evidence for
altered growth factor signalling, particularly involving
erbB family members in this process [6].
An intimate relationship exists between the tumour
and its surrounding microenvironment which can have a
major bearing on tumour development and progression
[7]. Importantly, our continued studies are suggestive
that the endocrine resistant phenotype may be signifi-
cantly sensitized towards factors likely to be present
within the tumour microenvironment [8] which may
also include growth factors that enhance erbB signalling.
We have recently identified that mRNA for the cell
surface protein, CD44, is upregulated in endocrine-
resistant breast cancer cells [9]. CD44, a family of trans-
membrane glycoproteins which arise through alternative
splicing of a common gene [10], are able to modulate
intracellular signalling through interaction with their
extracellular matrix ligand, hylauronan (HA), and
through formation of co-receptor complexes with vari-
ous receptor tyrosine kinases [11-13]. Indeed, increasing
evidence points to a role for CD44 as critical mediators
of both growth factor- and HA-induced mitogenic and
invasive signalling in cancer cells. For example, HA-
mediated mitogenic signalling has been suggested to in-
volve an interaction between CD44 and erbB family
members [14,15] whilst the v6 isoform (‘CD44v6’) is crit-
ically required for HGF/SF-mediated c-Met activation in
human cancer cells [11]. Clinically, several CD44 iso-
forms have been identified as potential metastatic deter-
minants as a result of an association between their
expression and extent of tumour spread and disease
stage [16]. Interestingly, further studies have shown that
CD44 can act to limit drug sensitivity in prostate cancer
cells [17] and in clinical ovarian cancer [18] but a rela-
tionship between CD44 and endocrine response in
breast cancer has not yet been reported.The fact that the primary CD44 ligand, HA, is also fre-
quently overexpressed in malignant cancers and has
been shown to be an independent prognostic factor for
overall survival in breast cancers [19] further suggests a
role for CD44-mediated signalling in breast cancer
progression.
In this study, we have investigated the hypothesis that
upregulation of CD44 in an acquired tamoxifen-resistant
state, may act to alter the phenotype of these cells
through both modulation of erbB signalling and a
sensitization of the cells to HA. We subsequently show
here that both heregulin and HA promote migratory sig-
nalling in the presence of elevated CD44 expression
through a process likely to involve modulation of erbB
herterodimerisation. These data thus suggest that CD44
upregulation in vivo may have significant bearing on the
progression of endocrine-resistant tumours through aug-
menting their cellular sensitivity to exogenous stromal
factors. Importantly, our preliminary findings also sug-
gest that the CD44v3 variant may act to limit endocrine
response in the clinic. Taken together, these data suggest
that CD44 may represent a novel point for intervention
to suppress progression of endocrine-resistant breast
cancer.
Results
CD44 is upregulated in tamoxifen-resistant MCF7 breast
cancer cells
Our previous RT-PCR analysis of tamoxifen-resistant
(‘TamR’) MCF7 cells revealed mRNA upregulation of the
standard form of CD44 ([9] and confirmed in Figure 1A).
Elevated levels of CD44 were subsequently confirmed at
a protein level by Western blotting (Figure 1B), which
revealed high levels of a protein of ~85kDa in TamR
cells versus MCF7 counterparts corresponding to the
expected size of CD44s. Analysis of CD44s expression
using immunocytochemistry (Figure 1C) revealed in-
tense staining in TamR cells, particularly at the cell
surface.
CD44 associates with the erbB2 receptor in TamR cells
Signalling through the erbB family of receptor tyrosine
kinases is known to play an important role in in vitro
models of tamoxifen resistance and is mirrored in clin-
ical disease [6,20]. Given the reported ability of CD44
molecules to modulate erbB receptor tyrosine kinase sig-
nalling though direct interaction with these proteins
[13], we used dual immunofluorescence staining to in-
vestigate whether CD44s and erbB receptors were
present in similar areas within the in TamR cell mem-
brane. Staining of unstimulated TamR cells revealed an
apparent co-localisation of CD44s and erbB2/erbB3
receptors (Figure 2). No endogenous association was
observed between CD44s and EGFR (data not shown).
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Figure 1 CD44s is overexpressed in tamoxifen-resistant breast
cancer cells. (A) mRNA expression of CD44s was investigated
through RT-PCR [L=DNA ladder; M=MCF7; T=TamR]. (B) Analysis of
CD44s upregulation at the protein level in tamoxifen-resistant (TamR)
cells was confirmed by Western blotting. (C) Immunohistochemical
staining of TamR cells demonstrated significantly elevated levels of CD44
staining compared with their endocrine-sensitive counterparts (C, scale
bar represents 20 μm).
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immunoprecipitation. Interestingly, some of the erbB3
staining appeared to be located to the nucleolus as pre-
viously reported [21,22]. Immunofluorescent analysis of
MCF7 cells was unable to demonstrate an association
between CD44 and erbB receptors primarily as erbB re-
ceptor expression was barely detectable in these cells
compared to their tamoxifen-resistant counterparts, as
previously reported [6].erbB2
merge merge
erbB3
Figure 2 CD44 is associated with erbB2 and erbB3 in TamR
cells. Immunofluorescence microscopy of CD44 (green) revealed a
largely cell-surface location. Subsequent staining of erbB2 and
erbB3 (red) and image overlay revealed apparent co-localisation
(yellow/orange) of these receptors in TamR cells.Inhibition of CD44 expression suppresses endogenous
erbB activity
We next explored the role of endogenous CD44 in
TamR cells using an siRNA-based approach. Treatment
of TamR cells with CD44 siRNA resulted in almost
complete suppression of CD44 gene (Figure 3A) and
protein (Figure 3B and Figure 4D) in contrast to the
non-targeting (NT) siRNA control.
Given that CD44 was seen to co-localise with erbB2 in
these cells and that CD44 has been implicated in erbB
receptor activation [13], we investigated whether re-
moval of CD44 would affect the endogenous activity of
erbB2. Our data demonstrated that levels of endogenous
phosphorylation of the EGFR were reduced following
CD44 siRNA (Figure 3B). Although a modest suppres-
sion of erbB2 activity was also seen, this tended to be ac-
companied by a small reduction in erbB2 proteinsuggesting that basal levels of erbB2 activation are not
greatly affected by the presence of CD44.
In light of these effects on intrinsic erbB activity,
known to play an important role in TamR cell phenotype
[6,23] we next explored the consequence of CD44
knockdown on TamR cell growth, migration and inva-
sion. Suppression of CD44 in TamR cells resulted in a
modest, but non-significant inhibition of TamR cell mi-
gration over fibronectin-coated membranes (Figure 4A)
whilst invasion through Matrigel was not affected
(Figure 4B). MTT growth assays revealed that TamR
cells lacking CD44 displayed a similar rate of growth to
that of their controls over a 5 day period (Figure 4C).
Further quantitative analysis of Ki67 staining in CD44-
deficient cells (Figure 4D and E) confirmed these data
and showed no significant change in proliferative index
versus their controls over this period.
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Figure 3 siRNA-mediated suppression of CD44 reduces
endogenous erbB activity in TamR cells. Treatment of TamR cells
with CD44 siRNA resulted in suppression of CD44 mRNA (A) and
protein (B, upper panel). Treatment of TamR cells with siRNA
delivery lipid (‘L) or a non-targeting siRNA (‘NT’) did not significantly
affect CD44 expression compared to untreated control (‘C’) cells. In
cells where CD44 expression was suppressed, the activity of EGFR
was also reduced.
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In view of our data supporting an association between
CD44 and erbB receptors in TamR cells, we next
addressed whether CD44 played a role as a regulator of
ligand-induced erbB activity and signalling. For these
experiments, CD44 expression was suppressed using
siRNA prior to ligand challenge with heregulin β1 (Hrg),
a potent activator of erbB signalling [24,25].
Treatment of control cells (TamR cells treated with
non-targeting siRNA) with Hrg resulted in phosphoryl-
ation of EGFR and erbB2 and activation of common
downstream signalling components ERK1/2, Akt, Src
and FAK (Figure 5A). However, in cells lacking CD44,
response to Hrg was significantly attenuated (Figure 5A),
particularly in the case of Hrg-induced EGFR phosphor-
ylation. Whilst a modest inhibitory effect was seen
regarding Hrg-induced ERK1/2 and Src activity, Hrg-
induced AKT phosphorylation was largely suppressed
following CD44siRNA treatment. Additionally, knock-
down of CD44 expression significantly suppressing Hrg-
induced migration (Figure 5B), invasion (Figure 5C) and
growth (Figure 5D) in these cells.
Hyaluronan induces migration in tamoxifen-resistant cells
which overexpress CD44
Hyaluronan (HA) is the natural ligand for the CD44 re-
ceptor and promotes signalling events which are
reported to mediate growth, survival, and migration in
cancer cells [26]. As such, we wished to test the hypoth-
esis that TamR cells, in which CD44 was over-expressed,
would display a greater sensitivity towards HA versus
their endocrine-sensitive MCF7 counterparts.
Treatment of both cell types with increasing concen-
trations of HA (0-200g/ml) promoted a modest (but
non-significant) increase in proliferation in TamR cells
only (Figure 6A) which also corresponded to an small
induction of ERK1/2 activity (Figure 6B). No such
changes were observed in MCF7 cells (Figure 6C,D).
Treatment of both cell lines with HA (200μg/ml) signifi-
cantly enhanced the migratory capacity of TamR cells
only in in vitro wounding assays (Figure 6E), effects
which were not apparent in the absence of CD44
(Figure 6F).
HA-induced TamR cell migration involves erbB activation
To explore whether erbB activation was involved in HA-
induced TamR cell migration, Western blotting was per-
formed on untreated and HA-stimulated TamR cells in
the absence or presence of CD44. HA induced EGFR,
erbB2 and ERK1/2 activation in the presence of CD44
(i.e. cells treated with the non-targeting siRNA control)
but not in cells treated with CD44siRNA (Figure 7A).
To further investigate the contribution of erbB signal-
ling to HA-mediated cell migration, TamR wounding
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Figure 4 Suppression of CD44 does not affect endogenous migration, invasion or growth of TamR cells. Boyden-chamber based
migration (A) and invasion (B) assays were used to determine the effects of CD44 suppression on the aggressive characteristics observed in TamR
cells. Suppression of CD44 in TamR cells did not significantly alter either their migratory (A) or invasive (B) capacity. The growth of TamR cells
after siRNA treatment was determined by MTT assay (C) and by staining for (D), and subsequent quantitation of (E), the proliferation marker, Ki67.
Suppression of CD44 expression did not alter the growth characteristics of these cells.
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presence or absence of the erbB2 inhibitor (trastuzumab)
or the EGFR inhibitor (gefitinib). Inhibition of either
erbB2 or the EGFR resulted in inhibition of HA-
mediated TamR migration (Figure 7B).
HA-mediated activation of CD44 alters erbB receptor
dimerisation patterns in TamR cells
The ability of HA to promote erbB activation in the ab-
sence of erbB ligand suggested that CD44 may act to
promote erbB dimerisation. To investigate this, we per-
formed immunoprecipitation using EGFR and erbB2
antibodies in the presence or absence of HA and also
following CD44 knockdown.
Analysis of endogenous erbB dimerisation patterns in
TamR cells revealed presence of EGFR:erbB2, erbB2:
erbB3 and erbB2:CD44 heterodimers whilst no signal
was detectable for control samples immunoprecipitated
with rabbit IgG (data not shown). No interaction was
detected between EGFR and CD44 under basal condi-
tions (Figure 8). HA stimulation of TamR cells resulted
in a change in erbB heterodimerisation pattern, with ap-
parent gains in erbB2:erbB3, erbB2:EGFR and EGFR:
CD44 associations. In contrast, association between theEGFR and erbB3 were lost in response to HA (Figure 8).
These changes in erbB dimerisation in response to HA
were not detected in cells treated with CD44 siRNA save
for erbB2:erbB3 heterodimers, which appeared to be par-
tially reduced.
Overexpression of CD44s in MCF7 cells enhances
HA-induced erbB activation and a migratory phenotype
To further investigate the role of CD44 in breast cancer
cells, we overexpressed CD44 in MCF7 cells which
have barely-detectable endogenous levels of this protein
(Figures 1 and 9A). Although overexpression of CD44s
in these cells did not appear to significantly alter the
endogenous activity of erbB2 or EGFR, treatment of
these cells with the CD44 ligand, HA, resulted in phos-
phorylation of both the EGFR and erbB2 and down-
stream activation of ERK1/2 (Figure 9B), an effect not
seen in MCF7 cells not over-expressing CD44.
The effect of HA on the proliferative and migratory
capacity of MCF7 cells overexpressing CD44 was next
tested. These experiments revealed that whilst HA did
not significantly alter the growth characteristics of
MCF7 control cells, MCF7 cells expressing CD44 dis-
played a partial response to HA in terms of growth
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Figure 5 CD44 suppression attenuates heregulin-induce invasive and migratory signalling in TamR cells. TamR cells were treated with
CD44 siRNA prior to treatment with the erbB lilgand, heregulin β1 (Hrg). Whilst Hrg promoted phosphorylation of erbB2 and the EGFR and
associated downstream signalling pathways in control cells (A) with a resultant gain in TamR cell migration (B), invasion (C) and growth (D), this
response was significantly attenuated in cells pre-treated with CD44siRNA. C: control (untreated) cells; L: siRNA transfection lipid alone; NT:
non-targeting siRNA; CD44: CD44siRNA. Controls in figures B, C and D represent samples treated with NT siRNA. *p<0.05 vs. untreated control;
**p<0.01 vs. Hrg-treated control.
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http://www.biomedcentral.com/1471-2407/12/458(Figure 9C). Similarly, whilst HA did not induce migra-
tory responses in control MCF7 cells, MCF7 cells
expressing CD44 displayed a significant gain in migra-
tion in response to HA (Figure 9D).CD44v3 is associated with shortened outcome on
tamoxifen in breast cancer patients
Our siRNA data implicates CD44 as an important medi-
ator of erbB signalling in ER+ breast cancer cells with
acquired tamoxifen resistance [27]. Previously, however,
expression of CD44s has been shown to be a favourable
prognostic marker in breast cancer. Since our siRNA ap-
proach suppresses a number of CD44 family members
(C. Smith, unpublished observations) we wished to in-
vestigate the prognostic significance of additional CD44
family members. To investigate this further, we con-
ducted preliminary analysis of CD44v3 expression in
a small series (n=67) of ER+ clinical breast cancers
by immunohistochemical staining. These data revealed
that patients with >median CD44v3 expression (by
H-score) had a shorter time to progression ontamoxifen (p=0.017) and a reduced overall survival
(p=0.028) (Additional file 1: Figure S1).Discussion
The phenomenon of acquired endocrine resistance con-
tinues to pose a substantial hurdle to the effective treat-
ment of breast cancer since clinical relapse frequently
presents as metastases. Data from in vitro breast cancer
cell models suggest that exposure to endocrine agents
results in an induction of signalling pathways in the
drug-responsive phase, which may include upregulation
of growth factor receptor expression/activity, that can
subsequently promote an endocrine-resistant state, both
sustaining growth in the presence of endocrine agent
and contributing to the development of an aggressive
phenotype. Identification of such endocrine-induced ele-
ments, particularly those with a pro-invasive function,
may represent potential therapeutic targets through
which endocrine resistance might be circumvented and
the resulting aggressive cellular characteristics associated
with resistance suppressed. Such approaches have met
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Figure 6 Hyaluronan promotes growth, migration and invasion in TamR cells. Treatment of TamR cells which naturally overexpress CD44
with the CD44 ligand, HA, resulted in a small but non-significant gain in growth (A) and an accompanying activation of ERK1/2 (B) which was
not seen in MCF7 cells (C, D). Treatment of TamR cells with HA also enhanced their migratory capacity, an effect not seen in MCF7 cells (E;
p=0.05 versus untreated cells). siRNA-mediated inhibition of CD44 expression in TamR cells prevented HA-induced cell migration (F, p=0.05 versus
CD44siRNA-treated cells); accompanying images are immunohistochemical staining of CD44 in NT- and CD44siRNA-treated TamR wound assays.
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EGFR [28] and Src kinase [29] in in vitro models.
In a previous study [9] we identified that expression of
the CD44 gene was elevated in cell models of tamoxifen
resistance. Although frequently used in conjunction with
CD24 as a marker for cancer stem cells [30], CD44 pro-
teins are also known to interact with, and modulate the
activity of a diverse range of receptor tyrosine kinases in-
cluding c-Met [31,32], VEGFR-2 [33], Her2 [34] and the
EGFR [35], the latter two having been previously shown
to limit endocrine response in ER-positive, endocrine-
sensitive disease and contribute to a gain in invasive
behaviour [6,20] [36-38]. Given the reported interplay
between CD44 and erbB receptors [15], we hypothesised
that CD44 expression may represent a key element in
the tamoxifen-resistant phenotype, potentially playing a
role in the development of the adverse cellular character-
istics accompanying this state.
Our data here revealed significant overexpression of
the standard CD44 isoform (CD44s) at both gene and
protein level in tamoxifen-resistant (‘TamR’) MCF7 cells
compared to their endocrine-sensitive counterparts.
However, CD44 did not appear to contribute to the
intrinsic aggressiveness of these cells. This was surpris-
ing since CD44 suppression resulted in a reduction
in endogenous EGFR activity and a modest suppression
of erbB2 phosphorylation, receptors known to have arole as mediators of cellular growth and migratory
responses. Interestingly, although we originally hypo-
thesised that CD44 - erbB2 interactions might be dom-
inant based on previous data supporting the interaction
of these receptors in other cell types (e.g. [39]), our
data here suggest that CD44:EGFR interactions are dom-
inant in TamR cells; an observation further supported by
our additional experiments which show a greater sup-
pressive effect on EGFR activity versus erbB2 activity
when CD44 is knocked down prior to stimulation of
the cells with the erbB ligand, heregulin, or through hya-
luronan stimulation.
Further analysis revealed that a number of common
intercellular signalling components including ERK1/2,
Src and AKT, known to be associated with erbB2 and
EGFR-induced cellular responses, were not greatly
affected on suppression of CD44 alone. These observa-
tions were further corroborated in MCF7 cells in which
CD44 was overexpressed; whilst these cells demon-
strated a small induction of endogenous EGFR and
erbB2 activity, there was no significant change in signal-
ling elements downstream of these receptors or to the
cells’ intrinsic migratory nature. No effects on the en-
dogenous growth of either cell type were seen following
CD44 suppression nor did removal of CD44 either re-
store tamoxifen sensitivity to the TamR cells or modulate
the response of MCF7 cells to tamoxifen (C. Smith,
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Figure 7 HA-induced erbB receptor activation in TamR cells promotes cell migration. (A) Treatment of TamR cells with HA is accompanied
by upregulation of activated EGFR, erbB2 and ERK1/2; this was not apparent in cells in which CD44 expression was suppressed using siRNA.
(B) To investigate the contribution of erbB signalling to HA-mediated cell migration, TamR wounding assays were performed in the presence of
HA and in the presence or absence of the erbB2 inhibitor (trastuzumab) or the EGFR inhibitor (gefitinib). Inhibition of either erbB2 or the EGFR
resulted in partial inhibition of HA-mediated TamR migration. *p=0.05 versus control.
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Figure 8 HA treatment promotes erbB dimerisation in TamR cells. TamR cells were treated with HA in the presence or absence of
CD44siRNA and immunoprecipitation performed using EGFR, erbB2 or CD44 antibodies. Subsequent Western blotting revealed that HA treatment
resulted in a shift in dimerisation pattern, with loss of EGFR:erbB3 and a gain in erbB2:erbB3, erbB2:EGFR and CD44:EGFR heterodimerisation. In
the absence of CD44 (by siRNA), HA did not affect erbB dimerisation.
Hiscox et al. BMC Cancer 2012, 12:458 Page 8 of 14
http://www.biomedcentral.com/1471-2407/12/458
M
CF
7
M
CF
7
CDA
CD44
actin
p-erbB2
- + - + HA
MCF7 MCF7CD
p-EGFR
actin
T-EGFR
T-erbB2
T-ERK1/2
p-ERK1/2
B C
0
100
200
300
400
500
600
700
800
900
0 50 100 200
MCF7 contol
MCF7 CD44
M
ea
n 
Ab
so
rb
an
ce
 U
ni
ts
[HA] ug/ml
*
*p<0.05 versus untreated
T=0
T=36hrs
MCF7 MCF7CD
D
Figure 9 Overexpression of CD44 in MCF7 cells augments their response to HA. (A) The standard isoform of CD44 was transiently
expressed in MCF7 cells and their response to HA subsequently examined using Western blotting and growth and migration assays. (B) HA
induced EGFR, erbB2 and ERK1/2 activity to a much greater degree in CD44-expressing MCF7 cells than their non-expressing control
counterparts. HA treatment of CD44-expressing MCF7 cells also promoted a small increase in proliferation (C) and a significant enhancement of
their migratory capacity (D).
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http://www.biomedcentral.com/1471-2407/12/458unpublished observations). Although together these data
suggested a minimal contribution of CD44 to the basal
phenotype of tamoxifen-resistant cells, further investiga-
tions revealed that CD44 expression significantly aug-
mented the cellular response to the exogenous erbB
ligand, heregulin, or to the CD44 ligand, hyaluronan,
factors known to be present in the tumour microenvir-
onment and which can influence tumour progression
and spread. Indeed, breast cancer-associated fibroblasts,
in contrast to those found in normal breast tissue, over-
express heregulin [40]; presence of this ligand promotes
MMP9 expression and secretion in breast cancer [41]
and is likely to enhance the cells’ invasive capacity
in vivo. Although early investigations of heregulins in
clinical breast cancer have failed to reveal an association
between their expression and prognostic parameters
[42,43], these studies tend to address expression of here-
gulin within the neoplastic epithelial cells rather than
within the tumour stroma. Recently, however, a study
analysing both epithelial and stromal heregulin expres-
sion in clinical tissues found that presence of heregulinwithin the stroma was significantly associated with dis-
ease recurrence and progression on endocrine therapy
[44]. In light of our observations that CD44 augments
heregulin sensitivity, we suggest that the presence of
CD44 on breast tumour cells in clinical tissue may fur-
ther aid identification of tumours less likely to respond
to conventional therapy, an effect likely to be exacer-
bated in instances where tumour CD44 and stromal
heregulins are co-expressed. Preliminary observations
suggest that MCF7 cells which overexpress CD44s
tended to display a reduced response to tamoxifen ver-
sus their wild-type counterparts, although this was not
significant (S. Hiscox, Unpublished data). Given that
overexpression of CD44 in MCF7 cells did not dramatic-
ally alter their intrinsic signalling capacity, one may
hypothesize that the true consequence of CD44 overex-
pression would be revealed only in the context of the
microenvironment, where exogenous ligands that can
activate CD44 would be present. This hypothesis is sup-
ported by studies which have shown that CD44 expres-
sion can modulate chemotherapy response in breast
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marily concerned with CD44, along with CD24, in the
context of its role as a marker for intrinsically drug-
resistant breast cancer stem cells. Others have demon-
strated that high levels of CD44 are present on a
doxorubicin-resistant MCF7-derived cell line [46]. How-
ever, in contrast, it has been recently described that high
levels of CD44 in clinical breast cancer are associated
with a more favourable prognosis [27].
It may also be likely that, rather than CD44 the level
of stromal HA might represent a determinant of drug
response and/or prognosis clinically and this remains to
be fully elucidated. The tumour microenvironment is
also a enriched with the CD44-ligand, HA, and in this
context HA may have a significant bearing on breast
cancer progression and spread through stimulation of
CD44-mediated signalling. Binding of HA to CD44 is
known to result in modification of the actin cytoskeleton
system through activation of Rac1 signalling with result-
ant formation of membrane ruffles, cellular projections
and induction of cell migration [47]. In addition, cluster-
ing of CD44, which may be induced by HA, has been
suggested to sequester MMP9 at the cell surface [48]
which may influence cellular invasion. Consistent with
its role in promoting CD44-mediated migration and in-
vasion, a number of studies have demonstrated that in-
hibition of HA production results in suppression of
in vivo tumour development and metastasis [49-51]. In
addition, HA expression in clinical breast cancer is a
strong, independent, and negative predictor for patient
survival [19,52]. Although HA-mediated activation of
CD44-associated receptor tyrosine kinases, including the
erbB2 receptor, has been described, little is reported on
whether erbB dimerisation is involved in this process.
Interestingly, our data supports a role for CD44 in medi-
ating the effects of HA through re-organisation of erbB
receptors, an event which may subsequently act to mod-
ify erbB signalling. Interestingly, HA appears to induce
erbB2:erbB3 heterodimer formation in a CD44-
dependent manner, a heterodimer pattern previously
implicated in driving heregulin-induced gefitinib resist-
ance [23]. That suppression of CD44 is able to deplete
heregulin-induced activation of erbB signalling and also
depletes HA-promoted erbB2:erbB3 association suggest
a potential value of therapeutically targeting CD44 in
breast cancer, potentially to improve the effect of current
targeted therapies.
An important aspect of CD44 activity is the relative
contribution of individual CD44 family members to the
development of adverse cellular features. Although our
evidence, along with published data, points to a role of
CD44s in these events, it should be noted that our
siRNA-based approach for suppressing CD44 likely
results in knockdown of multiple CD44 isoformsincluding CD44v3 and CD44v6 (S. Hiscox and C. Smith,
unpublished observations). Thus additional CD44 var-
iants may also contribute to augmentation of heregulin
of HA-mediated migratory signalling in TamR cells. This
is particularly important given that some studies in the
literature have failed to demonstrate a relationship be-
tween CD44s and tumour progression. For example,
CD44v3 is protective against mammary tumour growth
and metastasis in mice whereas CD44s is not [53]. In
primary breast tumours, CD44v6 expression correlates
with tumour size, nodal involvement and 5-year survival
[54] and, whilst this study did not explore CD44s ex-
pression, similar studies comparing CD44s and v6 ex-
pression in invasive breast carcinoma have reported no
correlation between CD44v6 and clinical outcome
whereas CD44s appears to be a favourable prognostic
factor [55]. Indeed, our own preliminary analysis of
CD44v3 in a small series of breast cancers reveals an as-
sociation with poor outcome on tamoxifen (Additional
file 1: Figure S1). Thus, it may be that whilst some CD44
isoforms provide a protective role, others may promote
adverse cellular features that could favour tumour pro-
gression. Moreover, although the HA-binding ability is
common to all CD44 isoforms, the contribution of indi-
vidual isoforms to erbB dimerisation and/or activation of
these receptors is currently unknown. It is possible that
one or more CD44 members may impart adverse cellular
characteristics, potentially through activation of erbB or
other receptors, onto tumour cells whilst other members
may have a neutral or even tumour inhibitory role. Sup-
porting such a hypothesis is data that suggests domin-
ance of CD44s over variant CD44 isoforms with respect
to promotion of tumour growth and spread. For ex-
ample, whilst HA stimulation of CD44s is suggested to
mediate breast cancer cell adhesion, motility and inva-
sion, HA stimulation of CD44 variants regulate only cell
motility [56]. Furthermore, induction of CD44s expres-
sion in MCF7 cells using a tetracycline-inducible system
resulted in in vivo breast tumour invasion and metasta-
sis to the liver [57]. Our in vitro data here suggests that
overexpression of CD44s enhances breast cancer cell
sensitivity to both erbB ligands and to HA and that sub-
sequent stimulation of CD44-overexpressing cells results
in modulation of erbB dimerisation and enhancement of
migration. These observations may present a mechanis-
tic explanation to recent reports which demonstrate that
a shift from CD44 variant isoforms towards the standard
isoform is required for cells to undergo EMT
in vitro and in vivo [58]. Clinical studies appear to fur-
ther establish CD44s over CD44 variants as a determin-
ant of tumour progression with, for example, CD44s
expression significantly correlating with lymph node in-
volvement in lung adenocarcinoma metastasis in con-
trast to CD44v6 [59].
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CD44s enhances breast cancer cell sensitivity to both
erbB ligands and to HA and that subsequent stimula-
tion of CD44-overexpressing cells results in modulation
of erbB dimerisation and enhancement of migration.
These observations may present a mechanistic explan-
ation to recent reports which demonstrate that a shift
from CD44 variant isoforms towards the standard iso-
form is required for cells to undergo EMT in vitro and
in vivo [58].
Conclusion
Our data here show here that acquisition of tamoxifen
resistance results in the overexpression of CD44 which
augments the cells’ sensitivity to ligands commonly
found within the tumour microenvironment. Our data
thus support an emerging role for CD44 as an important
determinant of breast cancer progression, particularly in
the setting of endocrine resistance.
Methods
Cell lines and reagents
Tamoxifen-resistant (‘TamR’) MCF7 breast cancer cells
were derived as described previously [6] and routinely
cultured in ‘experimental medium’ (phenol-red free
RPMI containing 5% charcoal-stripped, steroid-depleted
foetal calf serum, 10IU/ml penicillin, 10μg/ml strepto-
mycin, 2.5 μg/ml fungizone, 200mM glutamine), supple-
mented with 4-hydroxy tamoxifen (4-OH-Tam, 100nM).
Endocrine-responsive MCF7 cells were routinely grown
in phenol-red free RPMI containing 5% foetal calf serum
and antibiotics as above. Experiments comparing MCF7
and TamR cells were carried out in experimental
medium. Heregulin β-1 (Hrg, 10ng/ml) was purchased
from Sigma Ltd (Dorset, UK), medium molecular weight
hyaluronan (HA) from R+D systems (Oxford, UK) and
CD44siRNA from Dharmacon Ltd (ThermoScientific,
Leicester, UK). All antibodies were from Cell Signalling
Technologies (New England Bioloabs, Hertfordshire,
UK). All other reagents were from Sigma Ltd (Dorset,
UK) and consumables from GIBCO (Paisley, Scotland)
unless otherwise stated. Inhibitors were used at 1μM
(gefitinib) and 100nM (trastuzumab) unless otherwise
stated.
RT-PCR
MCF7 and TamR mRNA was reverse-transcribed to
cDNA and amplified using primers F: 5’ GAC ACA TAT
TGT TTC AAT GCT TCA GC 3’; R: 5’ GAT GCC
AAG ATG ATC AGC CAT TCT GGA AT 3’ which cor-
respond to the standard form of CD44 (CD44s). All PCR
reactions included primers specific for β-actin as an in-
ternal control and were performed in a semi-
quantitative manner using 27 cycles so that productswere in the linear range of amplification. PCR products
were visualised on a 1.0% agarose gel using ethidium
bromide and photographed.
siRNA-mediated suppression of CD44
siRNA knockdown of CD44 expression was performed
using a pool of CD44-specific siRNAs (Dharmacon)
according the manufacturers instructions. Briefly, TamR
cells were incubated with transfection lipid alone (Dhar-
mafect 1), lipid plus non-targeting siRNA (100nM) or
lipid plus CD44 siRNA (100nM) in culture medium for
48 hours after which cells were harvested and used in
the assays described below.
Stable transfection of MCF7 cells with CD44 gene
A cDNA corresponding to the standard form of CD44
and inserted into the pSRα-neo eukaryotic expression
vector [60] was introduced into MCF7 cells as follows:
briefly, MCF7 cells growing in log phase were washed
twice in serum-free RPMI then incubated for 6 hours
with serum-free RPMI containing the CD44 plasmid
(50μg) which had been pre-mixed with lipid (Lipofecta-
mine 2000, Invitrogen) at 37°C and 5% CO2. The DNA/
lipid-containing medium was then replaced with fresh
G418 (400μg/ml)-containing selection medium; cells
were maintained in selection medium for a further
48 hours after which confirmation of CD44 expression
was performed by Western blotting. Cells expressing
high levels (equivalent to that of TamR cells) were
selected and maintained in phenol-red free RPMI con-
taining 5% foetal calf serum, antibiotics as above and
G418 (200μg/ml).
Western blotting
Log phase cells (with or without prior treatment with
CD44 siRNA and with or without stimulation using
Hrg/HA as indicated in figure legends) were harvested,
lysed in Western lysis buffer (1% Triton x-100 in 50 mM
Tris, 150mM NaCl, 1mM EDTA, pH7.4 and containing
protease/phosphatase inhibitors) and equal amounts of
proteins resolved by 8% SDS-PAGE. Proteins were
immobilised on nitrocellulose membranes and probed
with CD44s (156-3C11, Neomarkers, Lab Vision, Chesh-
ire UK) or phospho-specific antibodies against EGFR
(pY845), erbB2 (pY1222), Akt (pS473), Src (pY419), FAK
(pY861) and ERK1/2 (pT202/S204). Repeat immuno-
probing was performed using pan antibodies and/or
actin or GAPDH as a housekeeping gene. Representative
blots are shown from a minimum of three separate
experiments.
Immunoprecipitation
Cells were lysed as described for Western blotting above and
lysates containing 1 mg protein were immunoprecipitated
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mouse IgG as a control overnight at 4°C. Protein A
agarose was added to the mixture, and the tubes were
placed onto a rotary mixer at 4°C for a further 2 h. The
immune complex was centrifuged at 3000 rpm at 4°C
for 5 min and washed with ice-cold lysis buffer. After
two further washings, the resultant pellet was resus-
pended in 20 μl loading buffer containing DTT, boiled
and processed as for Western blotting above.
Immunocytochemical analysis of breast cancer cell lines
MCF7 and TamR cells were grown to log phase on
tespa-coated coverslips. Cells were fixed with phenol/
formal saline and expression of CD44s detected using
antibodies as described above. Ki67 antigen detection
was performed using a the MIB-1 antibody (Coulter
Electronics, Luton, United Kingdom). Briefly, cells were
treated as indicated then washed and fixed in formal
saline. Primary antibody (MIB-1) was applied to the cov-
erslips after blocking with PBS/Tween and incubation
performed for 60 minutes. After washing in PBS, the
secondary antibody (Mouse Envision, DAKO UK Ltd.,
Ely, Cambridgeshire) was applied to the coverslips for
75 minutes. After further PBS washing, the chromogen
("SigmaFast" DAB, Sigma, Poole, UK) was added to the
cells for 10 minutes after which the coverslips were
rinsed in distilled water. Samples were counterstained
with 20% haematoxylin for 3 minutes and mounted for
examination by light microscopy. Control coverslips (no
primary antibody) were checked for non-specific binding
before assessing staining intensity in the test samples.
The percentage of Ki67-positive cells was estimated after
counting at least 1000 tumour cells.
Immunofluorescence
Log phase cells growing on coverslips were fixed in 3.7%
formaldehyde prior to incubation with anti-CD44 and
anti-erbB2 or erbB3 antibodies for 1 hour. After washing
and incubation with FITC or TRITC-conjugated second-
ary antibodies (for CD44 and erbB2 respectively), cover-
slips were mounted and viewed with a fluorescent
microscope. Images of CD44 and erbB2 were taken and
merged to investigate co-localisation
Migration/Invasion assay
Cells were seeded onto fibronectin-coated (100ug/ml,
migration assay) or Matrigel-coated (5mg/ml, invasion
assay), microporous membranes (8μm pore size) at
50,000 cells/membrane and cultured for a period of
48hrs. Migratory cells were then fixed, stained and
counted. Cell migration was quantified as the mean
number of cells observed in each of 5 random fields of
view per sample, in duplicate. Differences betweengroups were statistically compared using the student’s
t-test.
Wounding assay
Cells were grown to monolayer cultures in 24-well plates
(in presence/absence of siRNA) and then ‘wounded’ by
scratching the monolayer with a sterile yellow pipette
tip. After gentle washing, medium was replaced with
fresh medium containing appropriate treatments and the
cells cultured for a further 36 hours. After this time,
cells were fixed, stained with crystal violet and pictures
taking using a bright-field microscope. Statistical analysis
was performed using the student’s t-test.
Proliferation assay
Cell proliferation was determined using the MTT assay.
Briefly, cells were seeded into 96-well plates at 2000/well
and left to adhere for 24hrs. After this time, medium
was replaced with fresh medium containing treatments
as described and the cells cultured for a further 5 days.
The wells were then gently washed before addition of
MTT solution (2.5mg/ml) for 4 hours after which the
formazan crystals were solublized using 0.1% triton-
X100 and the absorbance of the wells read at 590nm.
Immunohistochemical staining for CD44v3 in breast
cancer tissues
An exploratory series of breast cancers (n=67) [61] was
used for immunohistochemical analysis of CD44v3. No
patient had previously received any form of adjuvant
endocrine or cytotoxic therapy. All breast cancer
patients had received systemic anti-hormonal therapy
and the duration of anti-hormonal response and survival
from the initiation of therapy monitored for each patient
by follow-up after surgery. Paraffin-embedded tissue sec-
tions were first subject to antigen retrieval by microwav-
ing for 30 min in 0.1 M citrate buffer (pH 6.0).
Following elimination of endogenous peroxidises with
3% hydrogen peroxide, immunostaining was performed
using the CD44v3 antibody and subsequent incubation
with DakoCytomation EnVision (30 minutes) and DAB
(1:50 dilution). Negative controls were incubated with
mouse isotype-sepcific control IgG (Dako).
All sections were assesses simultaneously by two obser-
vers blinded to the clinical data using a dual-viewing light
microscope at x40 magnification. Matched control slides
were checked for non-specific binding before assessment
of staining intensity with a minimum of 2000 tumour
cells evaluated per sample. The data were used to
construct a CD44v3 histopathology score (H-Score, range
1-300) for each tumour specimen as detailed previously [62].
Immunohistochemical analysis, Mann–Whitney U-test
was used to investigate the relationship between CD44v3
immunostaining and clinicopathological parameters. The
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(Kaplan-Meier method) were used to address the impact
of CD44v3 on survival from initiation of therapy or
on duration of therapeutic response. p<=0.05 was con-
sidered significant.
Additional file
Additional file 1: Figure S1. CD44v3 is associated with poor endocrine
response. Immunohistochemical analysis of CD44v3 expression in clinical
breast cancers revealed an association between high (>median H-score)
CD44v3 and both a shortened duration of response and overall survival.
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